Active, Not Recruiting
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors - CA017-076
Updated: 24 January, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1 - Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting - Participants must have an ECOG performance status of less than or equal to 1 - Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1 Exclusion Criteria: - Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease - Participants with prior exposure to anti PD-1 or anti-PDL1 therapy - Participants must not have a history of allergy to any of the study treatment components
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
